WallStreetZenWallStreetZen

NASDAQ: ABUS
Arbutus Biopharma Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ABUS stock forecasts and price targets.

Forecast return on equity

Is ABUS forecast to generate an efficient return?

Company
-6.24%
Industry
-16.28%
Market
132.06%
ABUS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABUS forecast to generate an efficient return on assets?

Company
-5.89%
Industry
-16.32%
ABUS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABUS earnings per share forecast

What is ABUS's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.75-5.65%
Avg 2 year Forecast
-$0.08-110.2%
ABUS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ABUS revenue forecast

What is ABUS's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$185.8M+2.27%
Avg 2 year Forecast
$4.2M-97.7%
ABUS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABUS earnings growth forecast

How is ABUS forecast to perform vs Biotechnology companies and vs the US market?

Company
-5.65%
Industry
23.31%
Market
1,173.47%
ABUS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ABUS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ABUS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ABUS revenue growth forecast

How is ABUS forecast to perform vs Biotechnology companies and vs the US market?

Company
2.27%
Industry
11.66%
Market
21.31%
ABUS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABUS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABUS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABUS$4.86N/AN/A
CGEM$14.95$39.00+160.87%Strong Buy
KURA$10.61$28.33+167.04%Strong Buy
MLTX$11.56$34.75+200.61%Strong Buy
ANL$15.40$30.80+100.00%Strong Buy
View Top Biotech Stocks

Arbutus Biopharma Stock Forecast FAQ

What is ABUS's earnings growth forecast for 2026-2027?

(NASDAQ: ABUS) Arbutus Biopharma's forecast annual earnings growth rate of -5.65% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,173.47%.

Arbutus Biopharma's earnings in 2026 is $153,054,000.On average, 3 Wall Street analysts forecast ABUS's earnings for 2026 to be $149,335,546, with the lowest ABUS earnings forecast at $143,479,250, and the highest ABUS earnings forecast at $153,727,768.

In 2027, ABUS is forecast to generate -$16,144,383 in earnings, with the lowest earnings forecast at -$15,511,270 and the highest earnings forecast at -$16,619,218.

If you're new to stock investing, here's how to buy Arbutus Biopharma stock.

What is ABUS's revenue growth forecast for 2026-2027?

(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of 2.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.31%.

Arbutus Biopharma's revenue in 2026 is $181,720,000.On average, 3 Wall Street analysts forecast ABUS's revenue for 2026 to be $36,768,041,656, with the lowest ABUS revenue forecast at $35,327,709,418, and the highest ABUS revenue forecast at $37,850,269,314.

In 2027, ABUS is forecast to generate $827,399,646 in revenue, with the lowest revenue forecast at $794,952,601 and the highest revenue forecast at $851,734,930.

What is ABUS's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: ABUS) forecast ROA is -5.89%, which is higher than the forecast US Biotechnology industry average of -16.32%.

What is ABUS's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ABUS) Arbutus Biopharma's current Earnings Per Share (EPS) is $0.80. On average, analysts forecast that ABUS's EPS will be $0.75 for 2026, with the lowest EPS forecast at $0.73, and the highest EPS forecast at $0.78. In 2027, ABUS's EPS is forecast to hit -$0.08 (min: -$0.08, max: -$0.08).

What is ABUS's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: ABUS) forecast ROE is -6.24%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.